Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.* 

4026-23: Retrospective Study on the Effects Of Extended-Release Naltrexone (XR-NTX) Injection Among Justice-Involved Adults Misusing Opioids Released from Correctional Facilities In Louisiana 

This presentation highlights the results of the first retrospective study on extended-released naltrexone offered by the Medication-for Opioid Use Disorder (MAT) Program by the Department of Corrections in Louisiana. Participants will learn how XR-NTX impacted treatment retention, relapse, and recidivism among justice-involved individuals misusing opioids released from correctional facilities in 2018 and 2019.

Presenters:  Isabelle Dubois, RN, BSN, MSc, PMHNP student; Sara Jones, PhD, APRN, PMHNP-BC, FAAN, FAANP

Disclosures:  The APNA planners and faculty have no relevant financial relationships to disclose. Off-label uses will not be discussed during this presentation.

Session Length:  30 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Discuss the clinical impact of extended-release naltrexone among justice-involved individuals misusing opioids upon eight weeks of re-entry.

Keywords:  Extended-release Naltrexone, Opioid Use Disorder, Justice-involved Individuals

Nursing Continuing Professional Development:
0.5 contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Price: Free through September 29, 2024 

Grant Statement:

Funding for this initiative was made possible (in part) by grant no. 1H79TI0855888-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Access to this course will end:  November 30, 2026

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.

Internet Explorer does not cooperate with this site. Please see below for options that work with APNA eLearning.*

3052-22:  Can We Help Psychiatric Nurses Stay? Implementation of a Unique, Comprehensive Psychiatric Mental Health Nurse Residency Program for Our Novice Psychiatric Nurses that Supports Professional Growth, Confidence, Critical Thinking, Teamwork, and Self-Awareness While Promoting Commitment and Retention 

This presentation provides a detailed overview of the development and implementation of a unique Psychiatric Mental Health Nurse Residency Program in a large psychiatric setting. Through engaged discussion, participants will leave with a framework and extensive outline to apply this professional development initiative in their own institution.

Presenters:  Nancy Bowllan, EdD, CNS, RN; Heather O'Brien, MSN, RN

Disclosures:  The APNA planners and faculty have no relevant financial relationships to disclose. Off-label uses will not be discussed during this presentation.

Session Length: 34 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Identify three learning outcomes and associated interactive learning activities in a Psychiatric Mental Health Nurse Residency Program.

Keywords:  Residency Program, Retention, Self-Care

Nursing Continuing Professional Development:
0.5 contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Originally Presented
APNA 36th Annual Conference
Long Beach, CA

The contact hours for this session expire:  November 30, 2025

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.

Internet Explorer does not cooperate well with this platform. Please see below for options that work best with APNA eLearning Center programs.*

APNA Suicide Prevention Certificate Program

This online certificate program builds the knowledge, skills, and critical thinking of psychiatric-mental health nurses (PMH-RNs) who care for persons at risk for suicide. This program content is presented by leaders in the field of psychiatric-mental health nursing with content matter expertise. 

The four-module course is self-paced with supplemental activities and resources, including handouts, glossary of terms, references, and other resources. It focuses on best practices and evidence-based nursing knowledge which data show increases PMH-RNs’ confidence in their individual practice, as well as their competence in the nursing skills of suicide prevention, assessment, and care management of persons at risk for suicide. 

Registrants have 90 days from date of registration to complete the full certificate program and earn nursing continuing professional development contact hours.

Target Audience:  PMH-RNs, RNs, and APRNs

Presenters:  Lori Johnson, RN-BC, MS; Rebecca Puchkors, MSN, RN, PMH-BC, CA-SANE; Jamie Zelazny, PhD, MPH, RN  

Disclosures:  The APNA planners and faculty have no relevant financial relationships to disclose. Off-label uses will not be discussed during this presentation. 

Learning Outcome:   
Upon completion of this program, the participant will:

• Report an increase in confidence and competence working with patients at risk for suicide. 

Course Outcome:   

• 75% of learners will report an intent to change practice as a result of completing this course.
  

Program Outline:

Module 1: Phenomenology of Suicide
Learning Objective: Discuss the phenomenology of suicide.

Module 2: Suicide Assessment and Risk Formulation
Learning Objectives:
• Perform a focused risk assessment. 
• Document patient level of risk for suicide. 
• Perform a suicide risk assessment. 

Module 3: Plan of Care
Learning Objective: Develop a collaborative Safety Plan. 

Module 4: Environmental Management
Learning Objective: Discuss environmental safety and risk mitigation.  

Keywords:  Suicide Prevention, Suicide Assessment, Suicide

Pricing:
APNA Member: $78 
Nonmember: $100
For organizations interested in purchasing the program in bulk, please email grouporders@apna.org

Nursing Continuing Professional Development:

5.0 contact hours. *To receive contact hours, participants must: complete all course modules, an evaluation, and an honor statement, as well as earn a passing score of at least 80% on all post-tests within 90 days from registration. You will have five tries to correctly answer the questions on the post-test. Credit cannot be earned unless all components of the program are completed. No partial credit can be awarded.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release Date:  March 21, 2024
Access to this course will end:  April 30, 2027

Cancellation Policy:
APNA does not issue refunds for eLearning purchases once the order is accomplished and the corresponding course information is accessed. However, we understand that exceptional circumstances can take place with regard to the character of the product we supply. Therefore, we do honor requests for a refund in situations outlined here. 

© APNA 2024. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.

Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.*

405-24: An Update on PANDAS Treatment and Research

Discuss the association between streptococcal infections and obsessive-compulsive disorder and updates in research to identify and treat the symptoms of PANDAS/PANS in children.

Presenter:  Kyle Williams, MD, PhD

Disclosures:  The APNA planners and faculty, with the exception of those listed below, have no relevant financial relationships to disclose. All relevant financial relationships listed for these individuals have been mitigated.  Off-label uses will be discussed during this presentation.

Kyle Williams, MD, PhD provides research support for Octapharma, USA, Alex Manfull Fund, and Fidelity Bioscience Research Initiative. Dr. Williams is a speaker for Octapharma, USA. During the last 24 months, Dr. Williams was a consultant for Pfizer, USA and provided research support for the International Obsessive Compulsive Disorder Foundation (these relevant financial relationships have ended).

Session Length:  1 hour 30 minutes

Target Audience:  APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Identify one treatment strategy to address the symptoms of PANDAS/PANS in children.

Course Outcome:

• 65% of learners will report an intent to make changes to their practice as a result of completing this course. 

Keywords:  PANS, PANDAS, Obsessive-Compulsive Disorder, OCD, Neuropsychiatric Syndrome, Autoimmune Disorder

Nursing Continuing Professional Development:
1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release date: July 8, 2024
Access to this course will end: July 31, 2026

© 2024 APNA. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.

Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.*

404-24: Grappling with Uncertainty: Managing Youth Suicide Risk

Suicide is the second leading cause of death in youth and the suicide rate has been increasing despite prevention efforts. Understand the public health reality of suicide, its disproportionate impact on youth, and how to apply evidence-based clinical strategies to recognize, manage, and prevent youth suicide.

Presenter:  John V. Campo, MD

Disclosures:  The APNA planners and faculty have no relevant financial relationships to disclose.  Off-label uses will not be discussed during this presentation.

Session Length:  1 hour 30 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Identify two evidence-based clinical strategies to recognize, manage, and prevent youth suicide.

Course Outcome:

• 65% of learners will report an intent to make changes to their practice as a result of completing this course. 

Keywords:  Youth, Suicide, Depression, Child, Adolescent, Suicide Prevention

Nursing Continuing Professional Development:
1.5 (0.5 of which are in pharmacology).  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release date: July 8, 2024
Access to this course will end: July 31, 2026

© 2024 APNA. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.

Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.*

403-24: Psychotropic Medications During the Perinatal Period: A Rational Approach to Prescribing

This presentation will give an overview of principles that can be used to guide psychotropic medication prescribing during the perinatal period.  The use of specific medication classes and their use during pregnancy and lactation will also be discussed.

Presenter:  Lyons Hardy, EdD, MSN, PMHNP

Disclosures:  The APNA planners and faculty have no relevant financial relationships to disclose.  Off-label uses will be discussed during this presentation.

Session Length:  1 hour 15 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Articulate at least two decision making strategies that should be used when prescribing psychotropic medications during the perinatal period.

Course Outcome:

• 65% of learners will report an intent to make changes to their practice as a result of completing this course. 

Keywords:  Perinatal, Psychotropic Medications, Prescribing, Pregnancy, Women's Health

Nursing Continuing Professional Development:
1.25 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release date: July 8, 2024
Access to this course will end: July 31, 2026

© 2024 APNA. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.

Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.*

402-24: Mixed States: When Bipolarity Complicates Diagnosis and Treatment of Depression

When the common symptoms of “mixed states” overlap extensively with PTSD, GAD, borderlinity and ADHD, and differentiating amongst them is nearly impossible, gain an understanding of when to use an antidepressant and treatment alternatives.

Presenter:  James Phelps, MD

Disclosures:  The APNA planners and faculty have no relevant financial relationships to disclose.  Off-label uses will be discussed during this presentation.

Session Length:  1 hour 30 minutes

Target Audience:  APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Recognize the overlap of depressed mixed states and other common diagnoses (PTSD, GAD, ADHD, borderline disorder) and risks of mis-directed treatment.

Course Outcome:

• 65% of learners will report an intent to make changes to their practice as a result of completing this course. 

Keywords:  Bipolar Disorder, Depression, Mania, Mood Disorders, Mixed States

Nursing Continuing Professional Development:
1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release date: July 8, 2024
Access to this course will end: July 31, 2026

© 2024 APNA. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.

Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.*

304-24: Pharmacology of Obesity and the Intersection with Psychopharmacology 

Review current anti-obesity medications and, through case studies that include patients with depression, anxiety, and severe mental illness, examine the intersection of obesity and mental illness.

Presenter:  Angela Golden, DNP, FNP-C, FAANP, FOMA

Disclosures:  The APNA planners and faculty, with the exception of those listed below, have no relevant financial relationships to disclose. All relevant financial relationships listed for these individuals have been mitigated. Off-label uses will not be discussed during this presentation.

Angela Golden, DNP, FNP-C, FAANP, FOMA is a promotional speaker for Novo Nordisk, Acella Pharmaceuticals, Currax Pharmaceuticals and Eli Lilly. Dr. Golden is on the advisory board for Boehringer-Ingelheim, WW, Novo Nordisk, Acella Pharmaceuticals, Currax Pharmaceuticals and Eli Lilly. During the last 24 months, Dr. Golden was on the advisory board for Gelesis (this financial relationship has ended). 

Session Length:  1 hour 30 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Recognize the impact of psychiatric medications on obesity and treatment options for reducing the weight gain associated with psychiatric medications.

Course Outcome:

• 65% of learners will report an intent to make changes to their practice as a result of completing this course. 

Keywords:  Obesity, Psychiatric Medications, Weight Gain, Mental Disorders, Antipsychotic Medications, Obesogenic Medications, Diet, Physical Activity, Exercise, Healthy Eating

Nursing Continuing Professional Development:
1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release date: July 8, 2024
Access to this course will end: July 31, 2026

© 2024 APNA. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.

Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.*

302-24: Benzos - How Early is Your Refill?

With anxiety being a common neuro-psychiatric symptom related with post COVID-19 infection, get crucial updates on how to prescribe and deprescribe this highly effective but controversial treatment option.

Presenter:  Daniel Wesemann, DNP, MSW, PMHNP-BC, ARNP, FAANP

Disclosures:  The APNA planners and faculty, with the exception of those listed below, have no relevant financial relationships to disclose. All relevant financial relationships listed for these individuals have been mitigated. Off-label uses will be discussed during this presentation. 

Daniel Wesemann, DNP, MSW, ARNP, PMHNP-BC, FAANP is a consultant for Neurocrine Biosciences. Dr. Wesemann was a consultant for Takeda Pharmaceuticals during the last 24 months (this relevant financial relationship has ended). 

Session Length:  1 hour 30 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Examine current best practices when considering prescribing benzodiazepines and appropriate deprescribing strategies.

Course Outcome:

• 65% of learners will report an intent to make changes to their practice as a result of completing this course. 

Keywords:  Anxiety, Neuropsychiatric Symptoms, Prescribing, Deprescribing, Depression, Stress, Insomnia, Antidepressants

Nursing Continuing Professional Development:
1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release date: July 8, 2024
Access to this course will end: July 31, 2026

© 2024 APNA. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.

Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.*

305-24: Nutritional Psychiatry: The Science of Food and Mental Health

Get insights into the many facets of nutritional psychiatry, including the gut microbiome and serotonin; prebiotics and probiotics; the connection between food, oxidative stress, inflammation and mood; and the effects of tea on GABA.

Presenter:  Mary Gutierrez, PharmD, BCPP

Disclosures:  The APNA planners and faculty have no relevant financial relationships to disclose.  Off-label uses will be discussed during this presentation.

Session Length:  1 hour 15 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Describe the effects of the gut microbiome on mental health and the implications of nutritional science in psychiatry.

Course Outcome:

• 65% of learners will report an intent to make changes to their practice as a result of completing this course. 

Keywords:  Nutritional Psychiatry, Gut, Microbiome, Mental Health, Nutritional Science, Mental Health Disorders, Diet, Supplements, Brain-gut Microbiome

Nursing Continuing Professional Development:
1.25 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release date: July 8, 2024
Access to this course will end: July 31, 2026

© 2024 APNA. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.